This study is designed to characterize the regional distribution of \[11C\] ABP688 in brain by positron emission tomography (PET).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
42
Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States
Binding of [11C] ABP688 to mGlu5 receptors
Binding of \[11C\]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes
Time frame: Day 1
Blood levels of [11C] ABP688
Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of \[11C\] ABP688. Specific times are recorded at the clinical site.
Time frame: Day 1, up to 60 minutes
Difference in [11C]ABP688 binding to mGlu5 receptors
Using data generated as described above, data will be analyzed to determine if there are difference in binding between healthy volunteers and patients.
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.